samedan logo
 
 
 
spacer
home > pmps > spring 2009 > supply chain strategies
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supply Chain Strategies

In the pharmaceutical industry, companies face challenges ranging from margin pressures and rising costs to complex regulatory environments and growing competition – and increasingly, they are viewing the supply chain as a key ingredient in meeting those challenges successfully. With that in mind, the 2008-2009 ‘Global Pharma Industry Supply Chain & Tech Ops Study’ was conducted in order to develop a deeper understanding of the nature and evolution of the supply chain in the industry. The study involved 17 pharmaceutical and biotech companies across a variety of business segments and geographies, and was conducted under the guidance of a steering committee made up of major pharmaceutical manufacturers. By drawing on the experiences of industry participants, it aimed to provide a practical perspective that can help companies strengthen their ability to use the supply chain as a key driver of high performance.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Jay Welsh is a partner in Accenture’s Pharmaceutical & Medical Products Supply Chain practice out of the firm’s Boston office. He is the global lead for Accenture’s Clinical Supplies practice and Supply Chain Merger Integration practice. Jay is also the executive sponsor for the 2008 Pharmaceutical Industry Best Practices Study in Technical Operations & Supply Chain. Focusing on supply chain strategy, R&D, technical operations and merger integration, he has teamed up with both large and small pharma and biotech clients to reduce costs, increase revenues, improve customer service and drive strategic advantages within the marketplace.

spacer
Jay Welsh
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Joining forces against SARS-CoV-2

Laupheim, Germany and Milford, MA, USA, October 08, 2020 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement